Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- NYMX
- Price
- -
- Stock movement down
- -0.06 (-11.77%)
- Company name
- Nymox Pharmaceutical Corp
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology & Medical Research
- Market cap
- 42.68M
- Ent value
- 45.69M
- Price/Sales
- -
- Price/Book
- -
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -22.03%
- 1 year return
- 16.90%
- 3 year return
- -41.95%
- 5 year return
- -28.99%
- 10 year return
- -24.58%
Last updated: 2024-12-17
DIVIDENDS
NYMX does not pay dividends or no data was received
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | 43.28 |
| EV to EBITDA | 46.34 |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | - |
| Price to Book | - |
| EV to Sales | - |
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 91.27M |
| EPS (TTM) | -0.13 |
| FCF per share (TTM) | -0.05 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 0.00 |
| Gross profit (TTM) | 0.00 |
| Operating income (TTM) | 769.00K |
| Net income (TTM) | -11.58M |
| EPS (TTM) | -0.13 |
| EPS (1y forward) | - |
Margins
Loading...
Margins data
| Gross margin (TTM) | - |
| Operating margin (TTM) | - |
| Profit margin (TTM) | - |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 132.00K |
| Net receivables | 10.00K |
| Total current assets | 214.00K |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 0.00 |
| Total assets | 271.00K |
| Accounts payable | 0.00 |
| Short/Current long term debt | 805.00K |
| Total current liabilities | 3.15M |
| Total liabilities | 3.15M |
| Shareholder's equity | -2.88M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -4.71M |
| Capital expenditures (TTM) | 3.00K |
| Free cash flow (TTM) | -4.72M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | - |
| Return on Assets | -4273.06% |
| Return on Invested Capital | 558.88% |
| Cash Return on Invested Capital | 227.61% |
STOCK INFORMATION
Downside potential
Loading...
Downside potential data
| NYMX | S&P500 | |
| Current price drop from All-time high | -96.33% | -6.88% |
| Highest price drop | -98.51% | -56.47% |
| Date of highest drop | 30 Jun 2023 | 9 Mar 2009 |
| Avg drop from high | -70.68% | -11.07% |
| Avg time to new high | 720 days | 12 days |
| Max time to new high | 6407 days | 1805 days |
COMPANY DETAILS
Marketcap
42.68M
Marketcap category
Small-cap
Description
Nymox Pharmaceutical Corporation, a biopharmaceutical company, engages in the research and development of drugs for the aging population in Canada, the United States, Europe, and internationally. Its lead drug candidate is Fexapotide Triflutate (NX-1207), which is in various clinical trials for the treatment of benign prostatic hyperplasia and low grade localized prostate cancer, as well as is in preclinical studies for hepatocellular carcinoma. The company also develops and markets NicAlert for detecting tobacco product usage; and TobacAlert for detecting second-hand smoke exposure. In addition, it develops drugs for the treatment of Alzheimer's disease. Nymox Pharmaceutical Corporation was founded in 1989 and is headquartered in Nassau, the Bahamas.
Employees
0
Website
Investor relations
-
SEC filings
CEO
Paul Averback
Country
USA
City
Nassau
Stock type
Common stock
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
No items found
iO Charts is a Seeking Alpha partner